Neurocrine Biosciences has agreed to acquire Soleno Therapeutics, Inc in an all‑cash transaction valued at approximately $2.9 billion, marking a significant expansion of its portfolio into rare genetic disorders.
Under the terms of the definitive agreement, Neurocrine will pay $53.00 per share in cash for Soleno’s outstanding stock. That price represents a premium of about 34 % over Soleno’s closing share price before the announcement, reflecting investor enthusiasm for the strategic rationale behind the transaction.
Deal Mechanics and Expected Timeline
The acquisition is structured as a cash tender offer, followed by a merger intended to complete the purchase of all remaining shares. Both Neurocrine’s and Soleno’s boards of directors have approved the transaction. The companies anticipate the deal will close within approximately 90 days, subject to customary regulatory approvals and the tender of a majority of Soleno’s shares.
Neurocrine plans to fund the acquisition primarily with cash on hand supplemented by a modest amount of pre‑payable debt, with no external financing condition noted in official disclosures.
Portfolio Expansion with VYKAT™ XR
A key driver of the acquisition is Soleno’s VYKAT™ XR (diazoxidecholine), a therapy that is FDA‑approved in the United States for the treatment of hyperphagia associated with Prader‑Willi syndrome, a rare genetic disorder characterized by persistent and excessive hunger.
VYKAT XR is the first and only U.S.‑approved treatment for this indication. By bringing the therapy into its portfolio, Neurocrine strengthens its presence in endocrinology and rare disease markets, areas of strategic focus for the company.
Market Response and Strategic Outlook
The acquisition news triggered a sharp rise in Soleno’s share price on April 6, with stock trading increasing by more than 30 % as investors reacted to the premium offer.
Industry analysts say the deal underscores Neurocrine’s commitment to expanding therapeutic offerings for underserved patient populations and enhancing its commercial pipeline with assets that address high‑impact rare conditions. The addition of VYKAT XR complements Neurocrine’s existing medicines and underscores the growing trend of consolidation in the biotech sector.
As the transaction moves toward regulatory review and shareholder approval, stakeholders will be watching how the combined capabilities of the two companies unfold in delivering broader care options for patients with rare endocrine and genetic disorders.
